NEWS BRIEF: Legend Biotech’s revenue doubles on big gains for CAR-T treatment
Cancer treatment maker Legend Biotech Corp. (LEGN.US) reported on Friday its revenue more than doubled to $187 million in the second quarter from $73 million a year earlier, while its…
Legend Holdings shows diversification isn’t always a winning formula
The investment holding company warned it will post a large loss for 2023, as losses from some assets may outweigh declining profits at others Key Takeaways: Legend Holdings warned that…
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US
-
Yalla revenue growth returns to double-digits ahead of new gaming push
YALA.US
